Last reviewed · How we verify

Sublingual allergy immunotherapy tablet

ALK-Abelló A/S · Phase 3 active Biologic

Sublingual allergy immunotherapy tablets work by exposing the body to small amounts of an allergen to build up tolerance and reduce symptoms.

Sublingual allergy immunotherapy tablets work by exposing the body to small amounts of an allergen to build up tolerance and reduce symptoms. Used for Treatment of grass pollen allergy symptoms.

At a glance

Generic nameSublingual allergy immunotherapy tablet
Also known asAcarizax, Odactra
SponsorALK-Abelló A/S
Drug classAllergen immunotherapy
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

This process, known as desensitization, involves the gradual introduction of increasing amounts of the allergen to the body, allowing the immune system to adapt and reduce its response. Over time, this can lead to a decrease in symptoms such as itching, sneezing, and congestion.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: